ArticlePloS one2014
Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis.BMC pulmonary medicine · 2020Pooled it
- [Meta-analysis of Platelet Lymphocyte Ratio as A Prognostic Factor for Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Pooled it
- The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis.Oncotarget · 2016Pooled it
- The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort.Scientific reports · 2016Pooled it
- Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.Scientific reports · 2016Pooled it
- Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Preoperative anemia is associated with prolonged hospital stay and increased facility discharges after glioblastoma resection.Frontiers in surgery · 2024Article
- A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.Cancers · 2023Review
- A comparison of inflammation markers for predicting oncological outcomes after surgical resection of non-small-cell lung cancer: a validated analysis of 2,066 patients.Scientific reports · 2020Article
- Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).Frontiers in oncology · 2020Article
- ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.Medical oncology (Northwood, London, England) · 2019Article
- Article
- Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients.Molecular and clinical oncology · 2017Article
- Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.Medicine · 2017Observational
- New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2017Article
- The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer.OncoTargets and therapy · 2016Article
- Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis.OncoTargets and therapy · 2016Article
- Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aims of this study were to investigate whether the preoperative hematologic markers, the neutrophil-lymphocyte ratio (NLR) or the platelet-lymphocyte ratio (PLR) were prognostic indicators and to develop a novel risk stratification model in pN0 non-small-cell lung cancer (NSCLC).
methodsWe performed a retrospective analysis of 400 consecutive pN0 NSCLC patients. Prognostic values were evaluated by Cox proportional hazard model analyses and patients were stratified according to relative risks for patients' survival.
resultsDuring the follow-up, 117 patients had cancer recurrence, and 86 patients died. In univariate analysis, age, gender, smoke status and tumor size as well as WBC, NEU, LYM, PLR and NLR were significantly associated with patients' prognosis. In multivariate analysis, age, tumor size and NLR were independent predictors for patients' overall survival (P = 0.024, 0.001, and 0.002 respectively). PLR didn't associated with patients' survival in multivariate analysis. Patients were stratified into 3 risk groups and the differences among the groups were significant according to disease free survival and overall survival (P = 0.000 and 0.000 respectively).
conclusionsWe confirmed that NLR other than PLR was an independent prognostic factor. Combination of NLR, age and tumor size could stratify pN0 NSCLC patients into 3 risk groups and enabled us to develop a novel risk stratification model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.